Growth Hormone Excess in Children with Optic Pathway Tumors Is a Transient Phenomenon.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

These children have elevated insulin-like growth factor 1 (IGF-1) levels, evidence of rapid growth despite treatment of precocious puberty, and failure to suppress GH levels following oral glucose challenge.

The aim of this report is to describe the treatment course and natural history of this rare clinical condition in 7 patients.

Who Took Part

According to the abstract, 7 patients were involved.

The age groups tagged for this paper are young children, children and teenagers, both men and women.

This is a descriptive case series of 5 children previously described and 2 additional children more recently diagnosed at their institution.

All 7 children had clinical and biochemical evidence of GH excess and received treatment with the somatostatin analog octreotide.

What Was Measured

The subject headings attached to it are Human Growth Hormone, Insulin-Like Growth Factor I, Neurofibromatosis 1 and Optic Nerve Neoplasms.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 7 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (Hormone research in paediatrics), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.